Dive Brief: The Food and Drug Administration has rejected an experimental cancer immunotherapy Eli Lilly and partner Innovent Biologics have been developing for a common …
Biohaven has built itself into a nearly $10 billion company on the strength of its migraine drug Nurtec, which surprised Wall Street with second-quarter sales …
The antibody treatments from Regeneron and Eli Lilly have been proven effective in reducing the risk of hospitalization or death from COVID-19 in certain high-risk …
Benlysta’s approval was itself a landmark, being the first such drug approved in decades. Its use has grown slowly and steadily over time, falling just …
